These results led to the assumption that lung cancer tumors harboring PIK3CA mutations could benefit from the inhibition of PI3K signaling and the combination of both PI3K and MEK inhibitors might show efficacy in KRAS-mutant lung cancers [31]. Here, MAP2K7 is linked to lung cancer.